Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Open access
Papadimitrakopoulou, Vassiliki, Lee, J. Jack, Wistuba, Ignacio I., Tsao, Anne S., Fossella, Frank V., Kalhor, Neda, Gupta, Sanjay, Byers, Lauren Averett, Izzo, Julie G., Gettinger, Scott N., Goldberg, Sarah B., Tang, Ximing, Miller, Vincent A., Skoulidis, Ferdinandos, Gibbons, Don L., Shen, Li, Wei, Caimiao, Diao, Lixia, Peng, S. Andrew, Wang, Jing, Tam, Alda L., Coombes, Kevin R., Koo, Ja Seok, Mauro, David J., Rubin, Eric H., Heymach, John V., Hong, Waun Ki, Herbst, Roy S.·2016·Journal of Clinical Oncology

Abstract

Purpose: By applying the principles of real-time biopsy, biomarker-based, adaptively randomized studies in non–small-cell lung cancer (NSCLC) established by the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, we conducted BATTLE-2 (BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer), an umbrella study to evaluate the effects of targeted therapies focusing on KRAS-mutated cancers. Patients and Methods: Patients with advanced NSCLC (excluding sensitizing EGFR mutations and ALK gene fusions) refractory to more than one prior therapy were randomly assigned, stratified by KRAS status, to four arms: (1) erlotinib, (2) erlotinib plus MK-2206, (3) MK-2206 plus AZD6244, or (4) sorafenib. Tumor gene expression profiling–targeted next-generation sequencing was performed to evaluate predictive and prognostic biomarkers. Results: Two hundred patients, 27% with KRAS-mutated (KRAS mut+) tumors, were adaptively randomly assigned to erlotinib (n = 22), erlotinib plus MK-2206 (n = 42), MK-2206 plus AZD6244 (n = 75), or sorafenib (n = 61). In all, 186 patients were evaluable, and the primary end point of an 8-week disease control rate (DCR) was 48% (arm 1, 32%; arm 2, 50%; arm 3, 53%; and arm 4, 46%). For KRAS mut+ patients, DCR was 20%, 25%, 62%, and 44% whereas for KRAS wild-type patients, DCR was 36%, 57%, 49%, and 47% for arms 1, 2, 3, and 4, respectively. Median progression-free survival was 2.0 months, not different by KRAS status, 1.8 months for arm 1, and 2.5 months for arms 2 versus arms 3 and 4 in KRAS mut+ patients (P = .04). Median overall survival was 6.5 months, 9.0 and 5.1 months for arms 1 and 2 versus arms 3 and 4 in KRAS wild-type patients (P = .03). Median overall survival was 7.5 months in mesenchymal versus 5 months in epithelial tumors (P = .02). Conclusion: Despite improved progression-free survival on therapy that did not contain erlotinib for KRAS mut+ patients and improved prognosis for mesenchymal tumors, better biomarker-driven treatment strategies are still needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.66.0084

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 183

Metadata

Authors
Papadimitrakopoulou, V., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., Gupta, S., Byers, L. A., Izzo, J. G., Gettinger, S. N., Goldberg, S. B., Tang, X., Miller, V. A., Skoulidis, F., Gibbons, D. L., Shen, L., Wei, C., Diao, L., Peng, S. A., Wang, J., Tam, A. L., Coombes, K. R., Koo, J. S., Mauro, D. J., Rubin, E. H., Heymach, J. V., Hong, W. K., & Herbst, R. S.
Venue
Journal of Clinical Oncology
Published
2016-10-20
Volume
34
Issue
30
Pages
3638-3647
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2500954855
Cited by
183
References
6
FWCI
18.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2015.66.0084
The paper
Papadimitrakopoulou, V., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., Gupta, S., Byers, L. A., Izzo, J. G., Gettinger, S. N., Goldberg, S. B., Tang, X., Miller, V. A., Skoulidis, F., Gibbons, D. L., Shen, L., Wei, C., Diao, L., Peng, S. A., . . . Herbst, R. S. (2016). The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.66.0084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.